Matrix metalloproteinase 14 is required for fibrous tissue expansion

  1. Susan H Taylor
  2. Ching-Yan Chloé Yeung
  3. Nicholas S Kalson
  4. Yinhui Lu
  5. Paola Zigrino
  6. Tobias Starborg
  7. Stacey Warwood
  8. David F Holmes
  9. Elizabeth G Canty-Laird
  10. Cornelia Mauch
  11. Karl E Kadler  Is a corresponding author
  1. University of Manchester, United Kingdom
  2. University of Cologne, Germany
  3. University of Liverpool, United Kingdom

Abstract

Type I collagen-containing fibrils are major structural components of the extracellular matrix of vertebrate tissues, especially tendon, but how they are formed is not fully understood. MMP14 is a potent pericellular collagenase that can cleave type I collagen in vitro. Here we show that tendon development is arrested in Scleraxis-Cre::Mmp14 lox/lox mice that are unable to release collagen fibrils from plasma membrane fibripositors. In contrast to its role in collagen turnover in adult tissue, MMP14 promotes embryonic tissue formation by releasing collagen fibrils from the cell surface. Notably, tendons grow to normal size and collagen fibril release from fibripositors occurs in Col-r/r mice that have a mutated collagen-I that is uncleavable by MMPs. Furthermore, fibronectin (not collagen-I) accumulates in tendons of Mmp14-null mice. We propose a model for cell-regulated collagen fibril assembly during tendon development in which MMP14 cleaves a molecular bridge tethering collagen fibrils to the plasma membrane of fibripositors.

Article and author information

Author details

  1. Susan H Taylor

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Ching-Yan Chloé Yeung

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Nicholas S Kalson

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Yinhui Lu

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Paola Zigrino

    Department of Dermatology, Center for Molecular Medicine, University of Cologne, Cologne, Germany
    Competing interests
    The authors declare that no competing interests exist.
  6. Tobias Starborg

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Stacey Warwood

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  8. David F Holmes

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  9. Elizabeth G Canty-Laird

    Department of Musculoskeletal Biology, Institute of Ageing and Chronic Disease, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  10. Cornelia Mauch

    Department of Dermatology, Center for Molecular Medicine, University of Cologne, Cologne, Germany
    Competing interests
    The authors declare that no competing interests exist.
  11. Karl E Kadler

    Wellcome Trust Centre for Cell-Matrix Research, Faculty of Life Sciences, University of Manchester, Manchester, United Kingdom
    For correspondence
    karl.kadler@manchester.ac.uk
    Competing interests
    The authors declare that no competing interests exist.

Reviewing Editor

  1. Robb Krumlauf, Stowers Institute for Medical Research, United States

Ethics

Animal experimentation: The care and use of all mice in this study was carried out in accordance with UK Home Office regulations, UK Animals (Scientific Procedures) Act of 1986 under the UK Home Office licence (PPL 40/3485). All animals were sacrificed by a Schedule 1 procedure by trained personnel. MMP14 KO mice were as described previously (Zhou et al., 2000). To generate mice in which MMP14 is ablated in tendon-lineage cells, we crossed mice expressing Cre recombinase under the control of Scleraxis (ScxCre; C57BL/6) (Blitz et al., 2013) with mice carrying the floxed exons (exons 2 to 4) of the MMP14 gene (MMP14-floxed; C57BL/6) (Zigrino et al., 2012). MMP13 KO embryos were a generous gift from Zena Werb (Stickens et al., 2004). MMP2 heterozygous mice were imported from RIKEN BioResource Center (GelAKO/RBRC00398; C57) (Itoh et al., 1997) and bred to homozygosity. Col-r/r mice were imported from Jackson Laboratory (B6;129S4-Col1a1tm1Jae/J) (Liu et al., 1995). X-ray analyses were performed as described previously (Yeung et al., 2014).

Version history

  1. Received: June 10, 2015
  2. Accepted: September 20, 2015
  3. Accepted Manuscript published: September 21, 2015 (version 1)
  4. Version of Record published: October 20, 2015 (version 2)

Copyright

© 2015, Taylor et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,668
    views
  • 615
    downloads
  • 43
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Susan H Taylor
  2. Ching-Yan Chloé Yeung
  3. Nicholas S Kalson
  4. Yinhui Lu
  5. Paola Zigrino
  6. Tobias Starborg
  7. Stacey Warwood
  8. David F Holmes
  9. Elizabeth G Canty-Laird
  10. Cornelia Mauch
  11. Karl E Kadler
(2015)
Matrix metalloproteinase 14 is required for fibrous tissue expansion
eLife 4:e09345.
https://doi.org/10.7554/eLife.09345

Share this article

https://doi.org/10.7554/eLife.09345

Further reading

    1. Cancer Biology
    2. Cell Biology
    Alex Weiss, Cassandra D'Amata ... Madeline N Hayes
    Research Article

    High-throughput vertebrate animal model systems for the study of patient-specific biology and new therapeutic approaches for aggressive brain tumors are currently lacking, and new approaches are urgently needed. Therefore, to build a patient-relevant in vivo model of human glioblastoma, we expressed common oncogenic variants including activated human EGFRvIII and PI3KCAH1047R under the control of the radial glial-specific promoter her4.1 in syngeneic tp53 loss-of-function mutant zebrafish. Robust tumor formation was observed prior to 45 days of life, and tumors had a gene expression signature similar to human glioblastoma of the mesenchymal subtype, with a strong inflammatory component. Within early stage tumor lesions, and in an in vivo and endogenous tumor microenvironment, we visualized infiltration of phagocytic cells, as well as internalization of tumor cells by mpeg1.1:EGFP+ microglia/macrophages, suggesting negative regulatory pressure by pro-inflammatory cell types on tumor growth at early stages of glioblastoma initiation. Furthermore, CRISPR/Cas9-mediated gene targeting of master inflammatory transcription factors irf7 or irf8 led to increased tumor formation in the primary context, while suppression of phagocyte activity led to enhanced tumor cell engraftment following transplantation into otherwise immune-competent zebrafish hosts. Altogether, we developed a genetically relevant model of aggressive human glioblastoma and harnessed the unique advantages of zebrafish including live imaging, high-throughput genetic and chemical manipulations to highlight important tumor-suppressive roles for the innate immune system on glioblastoma initiation, with important future opportunities for therapeutic discovery and optimizations.

    1. Cancer Biology
    2. Cell Biology
    Ian Lorimer
    Insight

    Establishing a zebrafish model of a deadly type of brain tumor highlights the role of the immune system in the early stages of the disease.